EPx4 Raises Odds of Renal, Nerve, Hearing Harms - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

  • By

  • Kerri Miller

  • February 25, 2026

  • 5 min

Share

  • 1

    Long-term survivors of testicular cancer treated with EPx4 face higher odds of renal impairment, ototoxicity, and peripheral neuropathy compared to BEPx3.

  • 2

    The study analyzed 798 patients who completed cisplatin-based chemotherapy, with a median follow-up age of 45 years and median time since treatment of 11 years.

  • 3

    Patients receiving EPx4 had 1.55 times the odds of renal impairment and 1.48 times the odds of hearing loss compared to those treated with BEPx3.

  • 4

    41% of patients exhibited reduced eGFR below 90 mL/min/1.73 m², exceeding US population norms, with significant associations to hypertension and cardiovascular disease.

  • 5

    Chemotherapy regimen significantly impacted self-reported global physical health, with BEPx4 and VIPx4 showing the most pronounced reductions in health scores.

Original Source(s)

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

  • by Kerri Miller

  • February 25, 2026

Related Content

10 Growing US Metro Areas to Consider for Private Practice

These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.

Does portal writing style contribute to disparities in clinician response?

Message length, punctuation, and clinician greetings were associated with intended clinician response.

Medical Oddities: Sheep wool gets into bone repair

From sheep wool to space guts, cannabis beats to tea: science took a wonderfully weird turn.